Facebook Pixel

Pradaxa (Dabigatran) Approved as Alternative to Warfarin for Reducing Atrial Fibrillation Stroke Risk

Rate This

The long-awaited alternative to Coumadin (warfarin) has just been approved by the United States Food and Drug Administration. The FDA just approved Pradaxa (dabigatran) for use by those with atrial fibrillation (afib) for preventing afib-related strokes.

The FDA based approval on results of the RE-LY trial, which saw patients on Pradaxa having fewer strokes than those on warfarin. And Pradaxa doesn't require the monitoring nor the restrictive diet that warfarin does.

Learn more at:

FDA Approves Pradaxa as Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation

Mellanie True Hills Bio

Add a Comment1 Comments

EmpowHER Guest

I took one150mg tablet per day for a month w/o any adverse reactions. I now have a prescription based on that and want to continue that same dosage but the manufacturers recommended dosage is 2 tablets per day. As a patient with two previous periods of Atrial Fib, will I not be relatively safe from clotting compared to the last seven years with just Plavix and baby aspirin. I am taking 2 tablets of Sotalol per day and wish to avoid further side affects.

February 8, 2011 - 11:21pm
Enter the characters shown in the image.
By submitting this form, you agree to EmpowHER's terms of service and privacy policy
Add a Comment

We value and respect our HERWriters' experiences, but everyone is different. Many of our writers are speaking from personal experience, and what's worked for them may not work for you. Their articles are not a substitute for medical advice, although we hope you can gain knowledge from their insight.

Atrial Fibrillation

Get Email Updates

Atrial Fibrillation Guide

Have a question? We're here to help. Ask the Community.


Health Newsletter

Receive the latest and greatest in women's health and wellness from EmpowHER - for free!